MwanzoARCT • NASDAQ
add
Arcturus Therapeutics Holdings Inc
$ 12.79
Baada ya Saa za Kazi:(0.47%)-0.060
$ 12.73
Imefungwa: 6 Jun, 19:17:14 GMT -4 · USD · NASDAQ · Kanusho
Bei iliyotangulia
$ 11.91
Bei za siku
$ 12.05 - $ 12.93
Bei za mwaka
$ 8.04 - $ 42.42
Thamani ya kampuni katika soko
346.87M USD
Wastani wa hisa zilizouzwa
elfu 445.45
Uwiano wa bei na mapato
-
Mgao wa faida
-
Ubadilishanaji wa msingi
NASDAQ
Kwenye habari
Fedha
Taarifa ya Mapato
Mapato
Mapato halisi
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato | 29.38M | -22.70% |
Matumizi ya uendeshaji wa biashara | 11.32M | -23.81% |
Mapato halisi | -14.08M | 47.51% |
Kiwango cha faida halisi | -47.91 | 32.09% |
Mapato kwa kila hisa | -0.52 | 48.00% |
EBITDA | -16.02M | 45.69% |
Asilimia ya kodi ya mapato | — | — |
Taarifa ya Hali ya Kifedha
Jumla ya mali
Jumla ya dhima
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Uwekezaji wa pesa taslimu na vipindi vifupi | 216.95M | -24.77% |
Jumla ya mali | 331.78M | -20.79% |
Jumla ya dhima | 98.03M | -36.71% |
Jumla ya hisa | 233.76M | — |
hisa zilizosalia | 27.12M | — |
Uwiano wa bei na thamani | 1.38 | — |
Faida inayotokana na mali | -12.45% | — |
Faida inayotokana mtaji | -15.41% | — |
Mtiririko wa pesa
Mabadiliko halisi ya pesa taslimu
| (USD) | Mac 2025info | Mabadiliko Tangu Mwaka Uliopita |
|---|---|---|
Mapato halisi | -14.08M | 47.51% |
Pesa kutokana na shughuli | -35.14M | -532.32% |
Pesa kutokana na uwekezaji | elfu -137.00 | 42.92% |
Pesa kutokana na ufadhili | 15.20M | 594.47% |
Mabadiliko halisi ya pesa taslimu | -20.08M | -456.39% |
Mtiririko huru wa pesa | -12.28M | -137.89% |
Kuhusu
Arcturus Therapeutics Holdings Inc. is an American RNA medicines biotechnology company focused on the discovery, development and commercialization of therapeutics for rare diseases and infectious diseases. Arcturus has developed proprietary lipid nanoparticle RNA therapeutics for nucleic acid medicines including small interfering RNA, messenger RNA, gene editing RNA, DNA, antisense oligonucleotides, and microRNA.
The company develops RNA therapeutics for the treatment of rare diseases such as ornithine transcarbamylase deficiency, and respiratory diseases such as cystic fibrosis. As of 2021, vaccine medicines include a vaccine candidate for COVID-19 and an influenza vaccine in the preclinical development phase. The vaccine for COVID-19 was authorised in Japan in 2023 and the European Union in 2025. Wikipedia
Afisa Mkuu Mtendaji (CEO)
Ilianzishwa
2013
Tovuti
Wafanyakazi
175
